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ABSTRACT 
Chromatin contains numerous different epigenetic marks, including histone-tail modifications 
and DNA methylation. Many of these marks have varying effects on the expression state of a 
gene at different points in development and life. However, there is accumulating evidence that 
these modifications do not act independently, and that interaction between epigenetic marks is 
necessary for proper cell function. Our previous study showed mutual antagonism between two 
epigenetic  marks,  histone  3  lysine  27  trimethylation  (H3K27me3)  and  DNA  methylation 
(DNAme), upstream of the promoter of the Rasgrf1 gene in mouse embryonic stem (ES) cells. 
H3K27me3 is deposited on chromatin by Polycomb Repressive Complex 2 (PRC2), and was 
shown to both restrict and be restricted by the placement of DNA methylation at this locus. Here, 
I  look at the methylation profiles of  DNA from wild type mouse ES cells  and cells with  a 
mutation in Eed of the PRC2 complex that results in a global loss of H3K27me3 to determine if 
this  mutual  antagonism  occurs  genome-wide.  Using  a  combination  of  a  Methyl  DNA 
Immunopreciptiation  microarray  (MeDIP-chip)  and  sodium  bisulfite  sequencing,  I  show  that 
H3K27me3 does indeed influence DNA methylation at numerous promoters in the embryonic 
mouse  genome.  Instead  of  seeing  a  consistent  increase  in  DNA  methylation  after  loss  of 
H3K27me3 however, I found that only some of these promoters showed DNAme enrichment, 
while others showed depletion in DNAme. Additionally, several genes were shown to have both 
DNAme  enrichment  and  depletion  in  the  same  promoter.  My  findings  suggest  that  mutual 
antagonism is not observed consistently genome wide, and that more complexity exists regarding 
the interaction between these two marks. 
  
2 
 
INTRODUCTION 
In  eukaryotes,  the  expression  of  genetic  material  is  regulated  not  only  by  transient 
transcription factors, but additionally by more permanent changes in its accessibility due to the 
rearrangement of chromatin(1). Chromatin, stored in the nucleus, is the association of DNA and 
several protein factors which include the nucleosome, an octomer of histone proteins that the 
DNA  is  wrapped  around.  The  rearrangement  of  chromatin,  due  to  factors  such  as  the 
modification to these histones and to the DNA itself, has an impact on the packing of genes and 
their ability to be expressed. Two classes of modifications that are given great attention are post-
translational modifications to histones and DNA methylation, which have been found to be key 
factors in pluripotency and the differentiation of the cell in early development.  
Types of Epigenetic Marks 
The N-terminal tails of histones are subject to several different covalent modifications, 
such  as  acetylation,  ubiquitination,  and  mono-,  di-,  and  trimethylation,  and  these  alterations 
affect how chromatin is packed. For some marks, such as acetylation, the presence or absence of 
the mark is correlated with activation or repression of transcription, regardless of which residue 
it is placed upon (2-5). Methylation of histone tail residues however, is much more specific; 
while methylation of lysine 4 on the tail of histone 3 (H3K4me) correlates with active chromatin 
transcription(6-8),  methylation  at  histone  3  lysine  9  (H3K9me)  facilitates  the  formation  of 
heterochromatin and gene silencing(8, 9). Trimethylation at Histone 3 Lysine 27 (H3K27me3) is 
a repressive mark that is placed on chromatin by the Polycomb Repressive Complex 2 (PRC2) 
and is associated with repression of genes during cellular development (10-14). 
  The  methylation  of  cytosine  nucleotides,  or  DNA  methylation  (DNAme)  is  also 
associated  with  repression  of  transcription.  It  primarily  exists  in  the  context  of  CpG  
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dinucleotides, and is usually found at most CpGs in the genome except at CpG-rich sites called 
CpG  islands.  These  islands,  usually  found  in  the  promoters  of  genes,  are  characteristically 
unmethylated,  except  in  the  case  of  transcriptional  repression,  present  in  both  healthy  and 
pathogenic cell types(15, 16).  DNA methylation is laid down in early development after a global 
demethylation  event  prior  to  implantation  (17-19).  This  de  novo  methylation  of  CpGs  is 
performed by DNA Methyltransferases (DNMTs), namely DNMT3a and DNMT3b (20), and 
later maintained by DNMT1 (21-23). CpG islands become methylated when cells look to repress 
transcription of that gene. This is true both in healthy cells, where active methylation of CpG 
islands  is  associated  with  imprinting,  X  chromosome  inactivation  and  the  repression  of 
transposable elements (15), and in cells that exhibit pathogenic phenotypes, where accumulation 
of methylation at these sites due to errors can cause genetic instability, pathogenic phenotypes, 
and cancer (16).  
These modifications distinguish different functional regions of chromatin, or chromatin 
states,  defined  as  the  culmination  of  all  of  the  epigenetic  modifications  at  that  region. 
Additionally,  these  epigenetic  modifications  are  reversible.  Methylation  for  example,  can  be 
passively demethylated by inactivity of DNMT1, or actively demethylated by proteins such as 
MBD2 and possibly the DNA repair pathway  (24). As a result, epigenetic states are able to 
change in certain cell types at several points and developmental stages in an organism’s life, and 
these states ultimately have an effect on overall gene expression at these times.  
Interaction Between Marks 
Recent research has shown that epigenetic marks do not act independently.  Instead, it has 
been  found  that  many  of  these  marks  collaborate  with  one  another,  require  one  another,  or 
antagonize each other to function properly (25). For example, in embryonic stem cells (ES cells),  
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repressive H3K27me and activating H3K4me3 are found to exist simultaneously at sites that 
code  for  developmental  transcription  factors  binding  keeping  genes  expressed  at  low  levels. 
However, this coincidence of marks, known commonly as a bivalent state, is thought to keep 
these genes “poised” for activation or silencing at a later time, and plays a role in the general 
developmental processes of an organism (14, 26). 
Placement  of  chromatin  marks  may  additionally  be  dependent  on  other  marks.  DNA 
methylation has indeed been shown to regulate deacetylation of histone residues (27, 28) and  
either prevent placement of methylation of H3K4 or actively demethylate  H3K4me3 (27, 29). In 
contrast, an increasing amount of evidence has  suggested DNA methylation requires histone 
methyltransferases for its placement. For example, EZH2, a component of the PRC2 complex, 
has been shown to directly interact with DNMT1, DNMT3A, and DNMT3B and be required for 
their  recruitment  (30).  This  finding  is  consistent  with  results  of  other  studies  linking  H3K9 
methyltransferase activity with DNA methylation (31-33). Additionally, unmethylated H3K4 has 
been demonstrated to recruit DNMT3L and facilitate de novo DNA methylation (34, 35), in 
seemingly direct opposition to the thought that it is the DNA methylation that influences H3K4 
methylation (27, 29). However, both of these findings may indeed show some truth, and if so 
provide  an  example  of  a  third  kind  of  interaction,  in  which  both  marks  affect  each  other 
simultaneously. This kind is best demonstrated in the observations of mutual antagonism. 
In  mutual  antagonism,  two  epigenetic  marks  impede  each  other’s  placement  on 
chromatin.  This  interaction  has  been  found  in  several  studies,  one  of  which  showed  that  in 
Arabidopsis thaliana, histone 2 variant H2A.Z and DNA methylation were shown to limit each 
other  (36).  Loss  of  H2A.Z  on  chromatin  due  to  a  mutation  in  the  Swr1  complex  led  to 
hypermethylation across the genome. Meanwhile enrichment and depletion of DNA methylation  
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on chromatin due to a mutation in the MET1 DNA methyltransferase of A. thaliana were shown 
to cause respective depletion and enrichments in H2A.Z at those same regions (36).  
Our own laboratory has demonstrated an example of mutual antagonism in mammals in 
the imprinting control region upstream of the Rasgrf gene in mouse stem cells (37). In one of our 
experiments,  treatment  of  mouse  embryonic  fibroblasts  (MEFs)  with  DNMT  inhibitor  5-
azacytidine showed increased concentration of H3K27me3 placement at the imprinting control 
region of the paternal allele, a region that is typically highly methylated. In another, artificially 
inducing  methylation  at  the  normally  unmethylated  maternal  locus  decreased  levels  of 
H3K27me3 usual to that region. Additionally, we found that deactivation of a functional PRC2 
complex in mouse embryoid bodies and trophoblast outgrowths led to a drop in H3K27me3 at 
the  maternal  locus  and  subsequent  presence  of  methylation  at  the  same  site.  We  therefore 
concluded that DNAme actively impedes the placement of H3K27me3, and that reciprocally, 
H3K27me3 blocks placement of DNAme at the Rasgrf locus (37). This finding is supported by 
evidence from proteomic analysis of HeLa S3 cells that Eed and SUZ12, components of PRC2, 
are depleted on methylated DNA (38). 
Mutual  antagonism  and  other  epigenetic  interactions  help  check  each  other  and  help 
establish  appropriate  epigenomic  states  for  proper  cell  function.  As  a  result,  errors  in  these 
interactions have been associated with pathogenic phenotypes (25). It has recently been shown 
for  instance  that  ChIP  analysis  of  colon  cancer  cells  show  colocalization  of  DNAme  and 
H3K27me3 (39, 40), in contrast with our recent study (37). Others support this claim, believing 
that in cancer this colocalization “locks in” stem cells temporary repressed via H3K27me3 by 
reinforcing  the  mark  with  DNAme  (41)  with  assistance  from  H3K9me  (42).  Learning  the 
mechanisms behind these chromatin mark interactions is crucial to understanding how they break  
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down in these periods of cell crisis, and whether they can be reconstituted to save a cell from 
cancer or developmental problems. 
Investigation of H3K27me and DNAme Mutual Antagonism 
Current  work  in  the  laboratory  is  looking  at  the  interaction  between  DNAme  and 
H3K27me3 genome-wide. Based on previous work (37), we are looking to determine if these 
two  repressive  marks  display  mutual  antagonism  in  promoters  outside  of  Rasgrf1.  If  such 
antagonism is present across the genome, we expect that the global depletion of one mark from 
chromatin will lead to the increase in the placement of the other. In this study, I look to answer 
half of this question, determining whether global depletion of H3K27me3 leads to an increase in 
DNAme at promoters in the mouse genome. 
My study utilizes two lines of mouse embryonic stem cells, the first being a wild type 
V6.5 strain, and the second being an eed
17Rn5-3554SB (eed
-/-) mutant, in which the Eed protein of 
the  PRC2 complex is rendered inoperable. Previous studies have shown that Eed is required in 
conjunction with EZH2 and SUZ12 for PRC2’s successful operation, with a mutation in the 
protein leading to loss of repression (43), and undetectable levels of H3K27me3 on chromatin 
(44). We additionally confirmed this loss of H3K27me3 by a western blot (J.A. Hagarman, in 
preparation).  As  a  result,  the  mutation  should  allow  us  to  test  whether  or  not  DNAme  has 
encroached on those spaces usually occupied by the histone mark in its absence 
To test the presence of DNA methylation, we first performed a genome-wide Methyl 
DNA  Immunoprecipitation  and  subsequent  cohybridization  of  DNA  from  both  strains  to  a 
promoter microarray (MeDIP-chip) on DNA from three replicate cultures of embryonic cells 
from each line (40). This array probed 50nt fragments within +1kb and -3kb of all promoters in 
the genome. Relative counts of methylated DNA from the V6.5 and eed
-/- cells were made at  
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each  50nt  probe,  and  these  counts  were  grouped  into  bins  of  100  nucleotides.  Aligning  the 
relative methylated DNA counts across the genome among all three replicates showed peaks of 
enrichment and depletion of DNAme within promoters of mutant. This method allowed us to 
identify which promoters showed changes in DNAme as a result of H3K27me3 depletion. We 
validated  these  results  by  confirming  a  number  of  peaks  via  bisulfite  sequencing.  Bisulfite 
sequencing uses sodium bisulfite to convert those unmethylated cytosine bases in DNA into 
uracils, which are later converted to thymidine bases after PCR. However, the sodium bisulfite 
will not react with methyl-cytosine, and will thus leave the identity of the nucleotide intact (45). 
As a result, short stretches of DNA can be sequenced for the presence or absence of DNAme at 
single nucleotide resolution (46). We utilized this method to validate a number of amplified 
fragments of DNA from the two cell types, each of which corresponded to a region flagged by 
the MeDIP-chip analysis as a peak.  
In summary, we used two independent methods to test our hypothesis that knockdown in 
levels of H3K27me leads to a global increase in DNA methylation at promoters across the mouse 
genome. Overall our data shows that H3K27me3 depletion does lead to significant changes in 
DNAme levels at ES cell promoters throughout the genome, and in many cases antagonized 
DNAme placement. In numerous other cases however, we found the converse phenomenon to be 
true,  where  H3K27me3  facilitated  placement  of  DNAme.  This  evidence  suggests  more 
complexity than a genome-wide trend of mutual antagonism between these two marks. 
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METHODS 
Extraction of DNA from ES cells 
The DNA used in the experiment was extracted by J.A. Hagarman from ES cells generated from 
a V6.5 wild type and Eed
17Rn5-3554SB (eed
-/-) mouse cell line and eluted in QIAGEN EB Buffer 
(J.A. Hagarman, in preparation). 
Methylated DNA Immunoprecipitation Microarray 
The MeDIP was performed by J.A. Hagarman using a protocol outlined by Mohn, 2009 (47), 
using  10ug  of  anti-5-MeC  antibody  (Eurogentec,  BI-MECY-0100)  in  IP  buffer  (10mM  Na-
Phosphate pH7, 140mM NaCl, 0.05% Triton), and anti-mouse M-280 Dynabeads (Invitrogen, 
112.01D) (J.A. Hagarman, in preparation). The immunoprecipitate was then amplified using the 
GenomePlex Complete Whole Genome Amplification kit (Sigma, WGA2), and  submitted to 
Cornell University Core Laboratories Facility, which ran the DNA on a NimbleGen Mouse DNA 
Methylation 3x720,000 CpG Island Plus RefSeq Promoter Array (NimbleGen, 05924537001). 
Three replicates of the cohybridization microarray were performed. Data analysis was performed 
by the Core Facility using NimbleGen NimbleScan© software under default settings. 
Bisulfite Treatment and PCR 
DNA extracted from ES cells was treated using the MethylEasy™ Xceed Bisulfite Conversion 
Kit  (Human  Genetic  Signatures,  ME002).  The  manufacturers  protocol  was  followed  as 
instructed, using 5μg of DNA in 20μL of DEPC H2O, and eluting with 20μL of 70ºC Reagent 5. 
I then amplified 2μL of the treated DNA from each sample in a 25μL PCR reaction using Ex 
Taq™ HS DNA Polymerase (TaKaRa). The conditions and mixture used mirrored that of the 
protocol  described  by  the  MethylEasy™  kit  (Mixture:  DEPC  H2O:  16.875μL;  10x  Ex  Taq 
Buffer: 2.5μL; 2.5mM ExTaq dNTP mixture: 2μL; 20μM Forward primer: .75μL; 20μM Reverse  
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primer: .75μL; 5U/μL Ex Taq DNA Polymerase: .125μL. Conditions: 95ºC 3 minutes; (95ºC 1 
minute; 50ºC 2 minutes; 72ºC 2 minutes)x32 cycles; 72ºC 10 minutes; 4ºC 30 seconds). Primers 
used are shown in Table 1. I then ran each PCR product on a 1.5% agarose gel, and excised 
bands of the appropriate size (see Table 1). Bands were then purified using the MinElute® Gel 
Extraction Kit (QIAGEN) using the manufacturer’s instructions for microcentrifuge use with the 
following alterations: elution buffer EB was preheated to 55ºC prior to elution, and the eluate 
was use to elute the column a second time to increase DNA yield. 
Ligation and Transformation of Treated DNA 
I  then  ligated  the  eluted  DNA  into  pCR®2.1-TOPO®  using  the  TOPO  TA  Cloning  Kit 
(Invitrogen,  45-0641)  and  transformed  these  vectors  into  TOP10  competent  cells  using  the 
manufacturer’s instructions. Cells were plated on ampicillin selective media, as well as X-gal for 
a  blue-white  screen,  and  incubated  overnight,  also  according  to  manufacturer  specifications 
(50μL and 100μL of inoculated SOC medium was used). Plates were stored at 4ºC following 
incubation.  I  analyzed  48  white  transformants  for  inclusion  of  each  fragment  using  a  PCR 
reaction outlined by the manufacturer, with the following alterations: (15μL Mixture: DEPC 
H2O: 9.7μL; 10mM dNTP: 30μL; Forward primer: .75μL; Reverse primer: .75μL, .2% BSA: 
.15μL, 5U/μL GoTaq® DNA polymerase: .15μL. Conditions: 95ºC 2 minutes; (95ºC 30 seconds, 
55ºC  30  seconds,  72ºC  1  minute)x40  cycles;  72ºC  5  minutes,  4ºC  1  minute).  Only  those 
transformants that clearly included the fragment of interest were used for sequencing. 
Transformant DNA Collection and Sequencing 
I grew 24 transformants of each amplicon and cell type (V6.5, eed) in 2mL LB cultures with 
ampicillin overnight. DNA from these cultures was then prepared using the QIAprep® Miniprep 
Kit  and  a  QIAvac  24  Plus  vacuum  manifold  (QIAGEN).  Manufacturer’s  procedures  were  
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followed, with the exception of the use of 40μL of elution buffer EB preheated to 55ºC prior to 
elution, and the use of EZ-10 Spin Columns (Bio Basic Inc) instead of the spin columns provided 
in the kit. Each set of 24 samples were then sequenced by a Illumina/Solexa Genome Analyzer 
through  the  Cornell  University  Core  Laboratories  Facility,  using  a  M13  Reverse  primer 
compatible with the pCR®2.1-TOPO® vector. 
Data Analysis of Bisulfite Sequencing 
Sequence reads  were compiled and analyzed using the online QUMA methylation  statistical 
software (http://quma.cdb.riken.jp/). At least 15 of the 24 DNA reads from both the treated V6.5 
line and treated eed
-/- line were compared with the reference sequence for differences in DNA 
methylation.  Clones  were  discounted  if  they  possessed  less  than  95.0%  percent  cytosine 
conversion or were less than 90.0% aligned with their genomic reference sequence. Results were 
evaluated using a Fishers Exact Test for methylation at each CpG. 
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Table 1: Primers Used To Validate DNA Methylation Peaks 
Each primer set from P1-P7 was used in pair to amplify the corresponding regions on later 
figures. Primer sets P1-P5 were designed by J.A. Hagarman. Primer Sets are named as they 
appear in the figures below. Those primer sets that are unlabeled were unable to be amplified for 
various reasons later mentioned, and were not used in later analysis. The laboratory code for 
each primer is also listed, as well as the direction of the primer and its melting temperature (Tm). 
 
Primer 
Set 
Gene 
Name 
Product 
Size 
Lab 
Code  F/R  Tm  Sequence 
P1  Gas5  421 
PDS1980  Forward  59  TGAATGTATTGTTTTTTGAGAGTAATTG 
PDS1981  Reverse  60  AAAAAACCCACCATCAAATAAAACT 
P2  Pdgfrl  425 
PDS1758  Forward  60  TTGTTATTGGATGGTTTTTGTTGTA 
PDS1959  Reverse  59  ACCCTTACTATCCTTAAACACACCA 
P3  Pdgfrl  482 
PDS1760  Forward  59  TGGTGTGTTTAAGGATAGTAAGGGT 
PDS1761  Reverse  59  TAAAAAAACCTTTTAAAAACCCCTC 
P4  Miip/Fv1  250 
PDS1835  Forward  58  GGTAAGGAATTTAATGATTTTGTGTATT 
PDS1836  Reverse  60  AAACTTCAATCTATTTTTCCCCAAC 
P5  Miip/Fv1  186 
PDS1839  Forward  58  ATAGGTAGTTAGTTGTAGGGGGTTG 
PDS1840  Reverse  58  CCAATAATTAATTATCACCAATTTTATTTA 
P6  Fbxo/ 
Ankrd16  240 
PDS1918  Forward  56  TTATAGTGGAGATAAGTTAGGTTTGTTAG 
PDS1919  Reverse  57  AAAAAACTTCCTATTATAAAATCTCCC 
P7  Fbxo/ 
Ankrd16  276 
PDS1926  Forward  58  AAGGATTAGAAATTTAAGAGAGATAAGGT 
PDS1927  Reverse  59  TTCCATAAACAACCCATAAATAACA 
--  Tnp1  257 
PDS1819  Forward  60  GGGGTTTAGTTGTGGAAGTATAAGG  
PDS1820  Reverse  56  AACAAAACTTACTAACTCATATACACCAT  
--  Tnp1  125 
PDS1821  Forward  60  AATTGAATAAATATGGGGGAGGTT  
PDS1822  Reverse  60  AAAAAATCTAACACCCAAAACATCA  
--  Prss21  289 
PDS1823  Forward  59  TTGTTTTTTGTAGTAATATGATGGATGA  
PDS1824  Reverse  62  CTACCCTAAACCCCATCACTCAAC  
--  Prss21  234 
PDS1825  Forward  60  GAGAGAGGTAGTTAGAGTTAGGGGTGT  
PDS1826  Reverse  56  ACATACAAACATAATACAACAATCAAA  
--  Prss21  260 
PDS1827  Forward  56  TTTAGTTTGATTGTTGTATTATGTTTG  
PDS1828  Reverse  59  ATCACATTAATCTTCCTACCTCTACCTC  
--  Miip/Fv1  288 
PDS1833  Forward  59  GGAAATAAAAGTTTGAAGATGAATTTTT  
PDS1834  Reverse  57  TTTATCCAAAAATACCAAAAACAAC  
--  Miip/Fv1  272 
PDS1837  Forward  56  GAGTTTAAAATTAGGAGGAGTTTTTT  
PDS1838  Reverse  60  AAAAACCTTCATTAAACACAATCCA  
--  Herc3  283 
PDS1841  Forward  60  TTTTTTTGTTTTGTGTTTTGGTTGT  
PDS1842  Reverse  56  CCTACATTAAACTTAAAAAATCTCAAAT 
--  Herc3  265 
PDS1843  Forward  60  AAAGGGGTAGGGGATTTATTATTTG  
PDS1844  Reverse  59  AACCAAATTTAACAAAAAATTCCAA  
--  Herc3  106 
PDS1845  Forward  59  TTGGAATTTTTTGTTAAATTTGGTT  
PDS1846  Reverse  56  CTTTATAAAAAACTTACCCAATTCC  
--  Herc3  281 
PDS1847  Forward  60  GGTAAGTTTTTTATAAAGTTTTTTTTGGG  
PDS1848  Reverse  56  CAATCACAACTACAAAACCTCTCT  
--  Herc3  160 
PDS1849  Forward  56  TTTGTAATAGAGTTGGTTTAGAGAGG  
PDS1850  Reverse  59  CAACCATCAACTAATAATAAACAACCA   
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--  Herc3 
 
181 
PDS1851  Forward  58  GAATGGTTGTTTATTATTAGTTGATGG  
PDS1852  Reverse  58  CAAATATAAAAAAATACAATCTCAACCTC  
--  Fbxo/ 
Ankrd16  207 
PDS1920  Forward  59  AGAGGATTTGTTTTTTTAGGTGTTG 
PDS1921  Reverse  57  AAAAAACTTCCTATTATAAAATCTCCC 
--  Fbxo/ 
Ankrd16  246 
PDS1922  Forward  58  GAAGGAAATTTTTTTAGAGTTTTTTAGA 
PDS1923  Reverse  60  CTAAAACCTAACTAACCCACCCCTA 
--  Fbxo/ 
Ankrd16  230 
PDS1924  Forward  59  GAGTTTTTTAGAGTTTTTTGGGTTTT 
PDS1925  Reverse  60  CTAAAACCTAACTAACCCACCCCTA 
--  Fbxo/ 
Ankrd16  286 
PDS1928  Forward  56  TTTGTAAGGAAGGAGTAGGTAGTTT 
PDS1929  Reverse  56  CAATTTCTTTACATTTAACAATACATTC 
 
 
    
13 
 
RESULTS 
ES cell deficiency in H3K27me3 causes DNAme enrichment in 861 genes 
The three independent MeDIP-chip experiments surveyed 20,404 promoters and 15,980 CpG 
islands.  Of these  regions,  the NimbleScan© software  found evidence of significant  DNAme 
changes  in  2,933  promoters  and  1,413  genes  according  to  the  Ensembl  annotation  of  the 
NCBIM37  assembly  of  the  mouse  genome.  The  three  arrays  were  shown  to  have  good 
correlation of peak intensities (0.74484,  0.70824,  0.64928, pairwise Pearson correlation).  Of 
these identified genes, 861 displayed increased DNAme in the eed
-/- cell line. Validation of one 
of the enriched peaks which correlated to a promoter of the Gas5 gene [Figure 1A] showed high 
significance  at  two  of  the  five  dinucleotides  (p<.01,  Fisher’s  exact  test)  in  the  amplicon, 
confirming that DNA methylation increased in the eed
-/- line [Figure 1B-D]. This gene was also 
shown to  be enriched for H3K27me3 in  the absence of DNAme, and is  believed to  exhibit 
mutual antagonism similar to that of Rasgrf1 (J.A. Hagarman, in preparation). Gene ontology 
analysis of those genes with increased DNA methylation in eed
-/- cells showed that many of these 
genes help operate either sensory perception or development (J.A. Hagarman, in preparation). 
ES cell deficiency in H3K27me3 causes DNAme depletion in 552 genes 
Despite those 861 genes showing increases in DNA methylation in the eed
-/- line, 552 genes of 
the 1,413 showed decreased methylation. These genes tended to have higher CpG content in their 
promoters  and  corresponded  with  chromatin  organization.  (J.A.  Hagarman,  in  preparation) 
Analysis of the two amplicons used to validate depletion of the promoter at the Pdgrfl growth 
factor  gene  [Figure  2A]  showed  only  one  peak  of  those  analyzed  showed  high  significance 
(p<.001, Fisher’s exact test) [Figure 2B-D]. Of the CpGs in the amplicon, site 36 was found to 
possess a single nucleotide polymorphism at site creating an artificial CpG site that was read as  
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significant. However despite this result, the significance of the one true CpG is still adequate in 
confirming a drop in DNAme at that site.  
ES cell deficiency in H3K27me3 causes both enrichment and depletions at 18 sites. 
In addition to identifying promoters which had only depleted or enriched levels, the MeDIP-chip 
also  identified  18  genes  that  showed  significant  levels  of  both  enrichment  and  depletion  in 
DNAme in the eed
-/- cells [Table 2]. Validation was performed for two of these promoters, one 
that encompasses the bidirectional promoters of Miip and Fv1 on chromosome 2 [Figure 3A], 
and  one  that  includes  the  Fbxo18  and  Ankrd16  genes  on  chromosome  4  [Figure  4A].  The 
bisulfite sequence data shows that three of the four CpGs found in the enriched amplicon of the 
Miip and Fv1 genes had significant increases in DNAme in eed
-/- cells (p<.035, Fisher’s exact 
test)  [Figure  3B,C,F],  and  both  CpGs  found  in  the  depleted  amplicon  of  the  gene  pair  had 
significant decreases in DNAme (p<.05, Fisher’s exact test) [Figure 3D, E,G]. Contrastingly, 
while one of the CpGs in the depleted amplicon of the Fbxo18-Ankrd 16 pair displayed a highly 
significant decrease in DNAme in the eed
-/- line (p<.0003, Fisher’s exact test) [Figure 4D,E,G], 
none of the 13 CpG sites tested in the enriched region of the pair showed any significant change 
in DNAme between the wild type and mutant lines [Figure 4B,C,F]. It should be noted however 
that the PCR product used to validate this amplicon existed at one end of the peak, and that 
differences in DNAme may still be found elsewhere within the peak, although due to bisulfite 
conversion  constraints  we  were  unable  to  design  primers  to  span  its  entirety.  I  should  also 
indicate that these seven amplicons were not the only regions surveyed, but that these were the 
only  products  of  24  [See  Table  1]  that  could  be  successfully  sequenced;  many  of  the  PCR 
products either failed to amplify, failed to be gel purified or ligated, or failed to be sequenced  
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[See Table 3]. Overall, three of the four peaks used to validate those genes with both enriched 
and depleted genes were confirmed, while one peak remains to be validated. 
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Table 2: Genes with  promoters  found to have enrichment and depletion in DNAme in 
H3K27me3 deficient ES cells 
Nucleotide position of the promoter regions found by the microarray to have both enrichment 
and depletion are shown, in addition to the names of the genes those promoters correspond to. 
Enrichment and Depletion scores are represented as log2 increases or decreases, based on sign. 
For those three gene pairs, both nucleotide start and end sequences for respective promoters are 
shown. 
 
Chr # 
Promoter 
Start 
Promoter 
End  Gene Name  Depletion (log2)  Enrichment (log2) 
1  196443022  196447022  Plxna2  -1.60  0.98 
2  11696379  11700379 
Fbxo18/Ankrd16  -1.22  1.38 
2  11698154  11702154 
4  113832988  113836988  Skint11  -1.55  1.24 
4  147240087  147244087 
Fv1/Miip  -1.95  1.48 
4  147241828  147245828 
5  147641465  147645465  Rpl21  -1.13  1.14 
6  52153586  52157586  Hoxa3  -1.21  1.29 
6  58856120  58860120  Herc3  -1.59  1.67 
7  92061290  92065290  Olfr290  -1.52  1.11 
7  110862109  110866109  Olfr243  -1.21  1.03 
8  36647851  36651851  Mfhas1  -1.23  2.2 
8  83014943  83018943  Gypa  -1.49  1.52 
8  109414539  109418539 
Chtf8/Cirhla  -1.13  2.53 
8  109416493  109420493 
9  110847662  110851662  Tdgf1/Crrc2  -1.00  1.58 
10  129310811  129314811  Olfr814  -1.39  1.67 
11  121688531  121692531  Ptchd3  -1.85  1.43 
14  80170119  80174119  Pcdh8  -1.37  1.50 
15  61813895  61817895  Myc  -1.28  1.09 
16  59215437  59219437  Olfr199  -1.44  1.43 
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Table 3: Summary of Procedures Performed and Success of Procedures 
The total number of laboratory procedures I performed in this experiment is listed with how 
many of these procedures succeeded in producing a relevant product for further experiments/data 
analysis. These procedures are outlined in Methods. A success of a Bisulfite PCR reaction was 
recorded as the presence of a definable band of DNA in the purification gel. As the amount of 
DNA  recovered  from  the  gel  purification  was  not  measured,  success  of  this  procedure  was 
recorded as whether the product purified was successfully transformed into cells in sufficient 
numbers to perform 48 transformant verification PCR reactions. A success of a transformant 
verification PCR reaction was defined as one where at least 24 of the transformants contained the 
desired  fragment.  The  success  of  a  sequencing  reaction  was  considered  as  a  PCR  fragment 
whose parallel sequencing produced at least 15 of 24 sequences that contained less than 10% 
sequence mismatches and less than 5% unconverted CpH dinucleotides as analyzed by QUMA. 
 
Procedure Type  Attempts  Successes  %  Success 
Bisulfite Treatment of DNA  14     
Bisulfite PCR  152  82  53.9 
Gel Purification, Ligation, and 
Transformation of Products 
100  56  56.0 
Transformant Verification PCR (x48)  42  32  76.2 
Sequencing Reaction (x24)  31  16  51.6  
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Figure 1. Validation of Enriched Methylation Peak at Gene Gas5. (A) The location of Gas5 in the mouse genome is shown 
above and data from the 3 MeDIP replicates is shown at bottom. Green vertical bars represent the log2 degree of enrichment of 
DNAme at the corresponding bin, while red vertical bars represent the log2 degree of depletion. The calculated average of the 
three replicates generated an enriched peak, shown as a green bar spanning the length of the peak. Also shown is a black bar 
indicating where the validation PCR product spans in relation to the peak (see Table 1). (B,C) The methylation profile of DNA 
at the PCR product P1 in V6.5 and eed-/- ES cells, respectively. Each circle represents one CpG as found in the product, and 
each row represents an independent clone used in the analysis. White circles indicate that the CpG was not methylated at that 
site, while black circles indicate methylation at that CpG. (D) A graphical comparison of methylation between V6.5 and eed-/- 
ES cells at each CpG site in PCR product P1.Blue bars indicate percent methylation among clones at a given CpG site in V6.5. 
Right adjacent yellow bars indicate percent methylation among clones in eed-/-. The horizontal axis shows relative position of 
each CpG in the PCR product. ** indicates high significance  at  p<.01 (Fisher’s exact test).  
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Figure 2. Validation of Depleted Methylation Peak at Gene Pdgfrl. (A) The location of Pdgfrl is shown with data from the 3 
MeDIP replicates. The calculated average peak of depletion is shown as a red bar spanning the length of the peak, and black bars 
indicating where the validation PCR products P2 and P3 spans in relation to the peak (see Table 1). (B,C) The methylation 
profile of DNA at products P2 and P3 in V6.5 and eed-/- ES cells, respectively. (D) A graphical comparison of methylation 
between V6.5 and eed-/- ES cells at each CpG site in PCR products P2 and P3. * indicates significance at p<.05 (Fisher’s exact 
test). *** represents a SNP at site 36 in which no CpG is found in the eed-/- cell line.  
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Figure 3. Validation of Depleted Methylation Peak at Gene Pair Fv1/Miip. (A) The location of the pair is shown with data 
from the 3 MeDIP replicates. The calculated average peaks of  enrichment and depletion are shown as green and  red bars 
spanning the length of the peak, respectively. Black bars indicate where the validation PCR products P4 and P5 span in relation 
to the peaks (see Table 1). (B,C) The methylation profile of DNA at product P4 in V6.5 and eed-/- ES cells, respectively. (D,E) 
The respective  methylation profile of DNA  at product P5 in V6.5 and eed-/- ES cells. (F, G) A  graphical comparison of 
methylation between V6.5 and eed-/- ES cells at each CpG site in PCR products P4 and P5, respectively. * indicates significance 
at p<.05 (Fisher’s exact test).   
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Figure 4. Validation of Depleted Methylation Peak at Gene Pair Fbxo18/Ankrd16. (A) The location of the pair is shown 
with data from the 3 MeDIP replicates. The calculated average peaks of enrichment and depletion are shown as green and red 
bars spanning the length of the peak, respectively. Black bars indicate where the validation PCR products P6 and P7 span in 
relation  to  the  peaks  (see  Table  1).  (B,C)  The  methylation  profile  of  DNA  at  product  P6  in  V6.5  and  eed-/-  ES  cells, 
respectively. (D,E) The respective methylation profile of DNA at product P7 in V6.5 and eed-/- ES cells. (F, G) A graphical 
comparison of methylation between V6.5 and eed-/- ES cells at each CpG site in PCR products P6 and P7, respectively. ** 
indicates high significance at p<.01 (Fisher’s exact test).   
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DISCUSSION 
Using  a  genome-wide  approach,  we  have  confirmed  that  H3K27  trimethylation  does 
indeed influence DNA methylation at numerous promoters in the genome of mouse ES cells. As 
discussed, mechanisms behind this interaction are not well understood. However, we found that 
DNAme is not widely antagonized by H3K27me3. Instead, some promoters showed enrichment 
in the absence of an operational PRC2 complex, while others showed a notable depletion in its 
absence, and a small few showed both enrichment and depletion. While our recent discovery of 
hypomethylation leading to increased H3K27 trimethylation provides evidence that both marks 
mutually regulate each other (Hagarman, in preparation), a global trend of mutual antagonism at 
promoters of genes must be ruled out in mouse embryonic stem cell lines.  
An  alternative  hypothesis  postulated  by  another  lab  is  that  the  PRC2  complex  may 
cripple  itself  by  binding  to  DNAme-poor  sites  and  recruiting  factors  that  induce  de-novo 
methylation of nearby chromatin, reducing its ability to methylate H3K27. This model is based 
on findings that DNA methylation by itself can inhibit PRC2 complex binding to chromatin and 
that PRC2 may recruit DNA methyltransferases in postnatal neural stem cells (48), and can be 
supported  by  our  findings  that  some  H3K27me3  depleted  regions  showed  decreased  DNA 
methylation. However, it is unlikely based on our lab’s previous studies that this alternative 
hypothesis is a global trend either (37). This demonstrates that the interaction between DNA 
methylation and H3K27me3 is likely to involve more than DNMT and PRC2 accessibility, and 
that a number of additional factors may dictate whether these marks coincide or are excluded 
from each other. 
One possible factor leading to the variation in H3K27 trimethylation’s effects on DNA 
methylation  could  be  PRC2’s  interaction  with  cis  DNA  elements  such  as  promoters  and  
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enhancers. It is possible that only certain sequences allow PRC2 to recruit certain DNMTs. Thus 
those  sequences  that  do  allow  placement  of  DNA  methylation  would  show  drops  in  DNA 
methylation  in  the  mutant,  and  those  sequences  that  prevent  PRC2  from  recruiting  certain 
DNMTs might show increases in DNA methylation when the chromatin may be more accessible 
for other DNMTs. This sequence specificity may be assisted by one of several cofactors that the 
core proteins of PRC2 associate with (49). However, while our study looked at gene function of 
those affected loci, we did not characterize cis DNA elements at these regions, and so further 
investigation into are data is required.  
Additionally, it should be noted that these findings only indicate interactions exhibited in 
mouse embryonic stem cells. Multiple studies have shown that after differentiation, chromatin 
marks  influence  each  other  differently.  For  example,  the  bivalent  chromatin  structure  of 
coinciding  activating  and  repressive  marks  described  by  Bernstein  et.  al.  is  lost  as  a  cell 
develops, and those cells formerly held in the “poised” state lose either H3K27me or H3K4me 
after differentiating (14). These differences between stem cells and differentiated cells is further 
supported by our finding that those genes that we identified as having this interaction mostly 
concern development; other genes involved in later processes may yet to be actively regulated.  
Thus, our study only captures a snapshot of epigenetic regulation when cells may exhibit a cycle 
of chromatin states as it passes through development.  Unfortunately, we cannot not identify 
changes amongst these mutants at later time points using similar methods; global inactivation of 
PRC2 allows cells to survive at the embryonic stage, but it is ultimately lethal to the fetus (50). 
Despite this limited look at chromatin state at this time point, some reports have indicated 
that some cancer cells may display epigenetic interactions similar to stem cells, supporting the 
stem  cell  hypothesis  of  tumorogenesis  (41).  Indeed,  a  similar  inverse  correlation  between  
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H3K27me3 and DNAme3 was found in colon cancer cell lines (40). If our findings are indeed 
stage-specific,  then these interactions  between  H3K27me3 and DNA  methylation  could  then 
serve as a model for how these marks are regulated in cancer cells as well as stem cells. This 
could then lead to finding means by which to inhibit these specific interactions, and the ultimate 
development of new anti-cancer drugs. 
Data collection for validation of methylation peaks came with extreme difficulty. One 
pitfall of using bisulfite treatment is that the conversion of unmethylated cytosines to thymines 
creates numerous problems in designing primers used for PCR. After bisulfite treatment, all non-
CpGs cytosines are converted to thymines, causing a loss in the complexity in the DNA. For a 
20bp primer for example, the number of unique sequences available drops from numbers in the 
low trillions to numbers in the billions. Additionally, primers must also be absent of any CpG 
dinucleotides in their sequence, as differences in methylation would create differences in primer 
annealing and amplification (51). Additionally, the conversion of cytosines to thymines can also 
permit hybridization of previously dissimilar genes, creating complex annealing and secondary 
structures that can confound sequencing efforts. Indeed, in our attempt to validate a peak in 
several unreported genes, sequence data received back from clones had consistent drop-offs after 
less than a hundred base pairs. Finally, the bisulfite process can be incredibly destructive to 
DNA, with the harsh conditions capable of degrading DNA during the denaturing and conversion 
steps.  At  many  times  during  data  collection,  DNA  was  unable  to  be  recovered  from  gel 
purification because no DNA viable for a PCR reaction remained after conversion. While the 
time over which these caustic steps are carried out can be limited to increase DNA yield, for 
larger PCR fragments this results in a large number of unconverted cytosines that render the 
sequence useless to analyze (51). As a result, neither I nor anyone else in the laboratory could  
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design primers that generated a product larger than 500bp. Consequently, combined with the 
reduced number of site-specific PCR primers available, we were unable to survey all sections of 
any given peak, since only few regions had sequences that matched these specifications. Despite 
these limitations however, I and my advisor were able to generate enough data to adequately 
validate the MeDIP-chip data. 
In summary, I found evidence that DNA methylation increases, decreases, or both at a 
number of gene promoters in mouse embryonic stem cell in the absence of an active Polycomb 
Repressive Complex 2, exhibiting a genome-wide interaction between DNA methylation and 
H3K27 trimethylation. Further work is being performed in our laboratory both to examine the 
levels of H3K27 trimethylation between wild type and DNMT triple knockout stem cells, and to 
identify transcript abundance of the affected genes amongst all three mutants – wild type, eed
-/- , 
and the DNMT mutant. We hope that these findings further elucidate the interaction between 
these two marks, and that further studies will discover the mechanism behind this interaction, 
whether direct or indirect. 
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